Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2001

View Archived Issues

VEGF gene therapy improves clinical status, myocardial perfusion and ischemia in angina

New treatment regimens of Zithromax recommended for approval in pediatric ear infections

Preclinical milestone achieved for SignalGene's SERM compounds

Preclinical results further validate Islet Neogenesis Therapy for diabetes

Ethics committee approval granted for PI-88 phase II trial in multiple myeloma

BioSante licenses vaccine technology to Corixa

Revised phase III plans for Endovasc's NRA and Liprostin

Traditional medicine used in Korea inhibits behavioral effects of psychostimulants

AMPA receptor antagonist ER-167288-01 ameliorates neurological status in MS model

Antioxidant strategy based on targeted enzyme induction may be beneficial in MS

Preclinical evidence supports the therapeutic potential of dexefaroxan in AD

Neurochemical effects of selective, oral AChE inhibitor from Chiesi studied in rats

Lundbeck offers interim progress report

Factor Xa inhibitor as a novel therapeutic agent in embolic stroke

New caspase inhibitor limits infarct size in rat model of cardiac ischemia/reperfusion injury

Prevention of carotid artery intimal hyperplasia by oral chymase inhibitor

FDA approves frovatriptan for treatment of migraine

Termination of PSVT with CVT-510 associated with fewer arrhythmias than adenosine

ImmunoGen highlights Q1 development progress

Enzyme targets for therapeutic intervention in AD

Use of growth factor in erectile dysfunction

Cathepsin K inhibitors and their use described in recent patent

Treatment of inflammatory and autoimmune diseases with new IL-2 inhibitors

MethylGene patents new histone deacetylase inhibitors for use in neoplastic diseases

Pharma Mar identifies novel antitumor compounds from marine sponge

Acetamide-based thrombin inhibitors synthesized at Merck & Co.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...